Favourable Long-Term Outcomes in Stage II/III TNBC With Atezolizumab Added to Chemotherapy, ctDNA Dynamics Provide Prognostic Value Beyond pCR By Ogkologos - July 28, 2025 748 0 Facebook Twitter Google+ Pinterest WhatsApp Final results from the IMpassion031 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR ΚΑΡΚΙΝΟΣ ΟΡΧΕΩΝ February 10, 2019 Long-Term Benefit of Nivolumab Plus Low-Dose Ipilimumab in Previously Treated Patients... June 30, 2022 Veteran Dresses As Captain America & Brings Joy To Children In... December 20, 2021 NCI Initiative Aims to Boost CAR T-Cell Therapy Clinical Trials April 23, 2020 Load more HOT NEWS 20 Adorable Tiny Homes That Are Perfect For A Peaceful Weekend... Could proton beam therapy improve throat cancer treatment? Immunotherapy approved for some people with oesophageal cancer on NHS in... Immune Pathways Help Identify Patients with Cancer and HIV Most Likely...
